VLADIMIR COSTA SILVA

Dr. VLADIMIR COSTA SILVA

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in EBioMedicine
Verified
Journal Article
Open access
Juliana Brambilla Carnielli TrindadeJuliana Brambilla Carnielli Trindade
Juliana Brambilla Carnielli Trindade
KCKathryn Crouch
Kathryn Crouch
SFSarah Forrester
Sarah Forrester
VSVLADIMIR COSTA SILVA
VLADIMIR COSTA SILVA
SCSílvio F.G. Carvalho
Sílvio F.G. Carvalho
JMJeremy C. Mottram
Jeremy C. Mottram
Miltefosine has been used successfully to treat visceral leishmaniasis (VL) in India, but it was unsuccessful for VL in a clinical trial in Brazil. To identify molecular markers that predict VL treatment failure whole genome sequencing of 26 L. infantum isolates, from cured and relapsed patients allowed a GWAS analysis of SNPs, gene and chromosome copy number variations. A strong association was identified (p = 0·0005) between the presence of a genetically stable L. infantumMiltefosine Sensitivity Locus (MSL), and a positive response to miltefosine treatment. The risk of treatment failure increased 9·4-fold (95% CI 2·11-53·54) when an isolate did not have the MSL. The complete absence of the MSL predicted miltefosine failure with 0·92 (95% CI 0·65-0·996) sensitivity and 0·78 (95% CI 0·52-0·92) specificity. A genotyping survey of L. infantum (n = 157) showed that the frequency of MSL varies in a cline from 95% in North East Brazil to <5% in the South East. The MSL was found in the genomes of all L. infantum and L. donovani sequenced isolates from the Old World (n = 671), where miltefosine can have a cure rate higher than 93%. Knowledge on the presence or absence of the MSL in L. infantum will allow stratification of patients prior to treatment, helping to establish better therapeutic strategies for VL treatment. FUND: CNPq, FAPES, GCRF MRC and Wellcome Trust.

9 November 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LGLuiz Gustavo Gardinassi
Luiz Gustavo Gardinassi
GGGustavo Rocha Garcia
Gustavo Rocha Garcia
CCCarlos Henrique Nery Costa
Carlos Henrique Nery Costa
VSVLADIMIR COSTA SILVA
VLADIMIR COSTA SILVA
ISIsabel Kinney Ferreira De Miranda Santos
Isabel Kinney Ferreira De Miranda Santos
Visceral leishmaniasis (VL) can be lethal if untreated; however, the majority of human infections with the etiological agents are asymptomatic. Using Illumina Bead Chip microarray technology, we investigated the patterns of gene expression in blood of active VL patients, asymptomatic infected individuals, patients under remission of VL and controls. Computational analyses based on differential gene expression, gene set enrichment, weighted gene co-expression networks and cell deconvolution generated data demonstrating discriminative transcriptional signatures. VL patients exhibited transcriptional profiles associated with pathways and gene modules reflecting activation of T lymphocytes via MHC class I and type I interferon signaling, as well as an overall down regulation of pathways and gene modules related to myeloid cells, mainly due to differences in the relative proportions of monocytes and neutrophils. Patients under remission of VL presented heterogeneous transcriptional profiles associated with activation of T lymphocytes via MHC class I, type I interferon signaling and cell cycle and, importantly, transcriptional activity correlated with activation of Notch signaling pathway and gene modules that reflected increased proportions of B cells after treatment of disease. Asymptomatic and uninfected individuals presented similar gene expression profiles, nevertheless, asymptomatic individuals exhibited particularities which suggest an efficient regulation of lymphocyte activation and a strong association with a type I interferon response. Of note, we validated a set of target genes by RT-qPCR and demonstrate the robustness of expression data acquired by microarray analysis. In conclusion, this study profiles the immune response during distinct states of infection of humans with Leishmania infantum with a novel strategy that indicates the molecular pathways that contribute to the progression of the disease, while also providing insights into transcriptional activity that can drive protective mechanisms. Infections of humans with the protozoan parasites L. donvani and L. infantum can lead to the development of the disease visceral leishmaniasis, but also to an asymptomatic status. However, the mechanisms that result in these clinical outcomes after infection are poorly understood. In this study, we applied a data-driven approach to obtain insights into the immunological processes linked to the progression of the disease or to protective mechanisms. For this purpose, we evaluated the patterns of expression for genes that code proteins from the entire human genome in the peripheral blood from patients with visceral leishmaniasis, from individuals who remained asymptomatic after infections with L. infantum, from patients who were recovering from disease after treatment and from uninfected individuals. By employing computational analysis to evaluate the blood transcriptional activity of each group, we identified transcriptional signatures that correlate with previous findings obtained through different analytical methods. Moreover, our analyses uncovered hitherto unidentified molecular pathways and gene networks associated with the transcriptional profiles of individuals recovering from disease or that did not develop symptoms after infection. This suggests that activation of protective responses can be useful targets for the development of new therapies for visceral leishmaniasis.

1 February 2007 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
RGRegis B. Gomes
Regis B. Gomes
IMIvete L. Mendonça
Ivete L. Mendonça
VSVLADIMIR COSTA SILVA
VLADIMIR COSTA SILVA
JRJerônimo Ruas
Jerônimo Ruas
MSMauro B. Silva
Mauro B. Silva
CCCarlos H.N. Costa
Carlos H.N. Costa

1 September 2009 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
MZMaysa F. Zampa
Maysa F. Zampa
IAInês M.S. Araújo
Inês M.S. Araújo
VSVLADIMIR COSTA SILVA
VLADIMIR COSTA SILVA
CCCarlos H. Nery Costa
Carlos H. Nery Costa
JSJosé Ribeiro Santos
José Ribeiro Santos
Jose Roberto LeiteJose Roberto Leite
Jose Roberto Leite

7 March 2021 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AOAna R. Soares de Oliveira
Ana R. Soares de Oliveira
KCKyria Cruz
Kyria Cruz
JMJennifer Beatriz Silva Morais
Jennifer Beatriz Silva Morais
LSLoanne Rocha Dos Santos
Loanne Rocha Dos Santos
SMStéfany Rodrigues de Sousa Melo
Stéfany Rodrigues de Sousa Melo
DMDilina Marreiro
Dilina Marreiro

17 June 2013 in Molecules
Verified
Journal Article
Open access
PDF file
GBGuilherme Brand
Guilherme Brand
RSRaimunda C. Santos
Raimunda C. Santos
LALuisa Mayumi Arake
Luisa Mayumi Arake
VSValdelânia G. Silva
Valdelânia G. Silva
LVLeiz Véras
Leiz Véras
Jose Roberto LeiteJose Roberto Leite
Jose Roberto Leite
Antimicrobial peptides (AMPs) from the dermaseptin and phylloseptin families were isolated from the skin secretion of Phyllomedusa nordestina, a recently described amphibian species from Northeastern Brazil. One dermaseptin and three phylloseptins were chosen for solid phase peptide synthesis. The antiprotozoal and antimicrobial activities of the synthetic peptides were determined, as well as their cytotoxicity in mouse peritoneal cells. AMPs are being considered as frameworks for the development of novel drugs inspired by their mechanism of action.